Dravet syndrome is a terrible disease generally caused by mutations of the SCN1A gene. Recently others genes such as STXBP1 have been involved in the pathogenesis of the disease. The STXBP1 mutation in patients with Dravet Syndrome may additionally causes several parkinsonian features usually attributed to carriers of the SCN1A mutation. Management continues to be difficult; that is why Cannabidiol emerged as valid option for treatment of this condition.
January 16, 2019
New Review Study Supports Ability of Epidiolex to Reduce Seizure Frequency in Dravet, Lennox-Gastaut Patients
Researchers in this study reviewed the main findings of these trials regarding the safety, efficacy, and tolerability of Epidiolex for the treatment of children with Dravet and Lennox-Gastaut syndromes.
January 13, 2019
Central Nervous System Lymphatic Unit, Immunity and Epilepsy: Is There a Link?
Disruption of fluid drain rules related to the central nervous system may promote or sustain central nervous system disease, conceivably applicable to epilepsy where extracellular accumulation of macromolecules and metabolic by?products occur at the interstitial and perivascular spaces.